Continuum Advisory LLC Purchases Shares of 2,596 IQVIA Holdings Inc. $IQV

Continuum Advisory LLC purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, HoldingsChannel reports. The firm purchased 2,596 shares of the medical research company’s stock, valued at approximately $502,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC boosted its holdings in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 2,537 shares during the last quarter. Empowered Funds LLC boosted its stake in shares of IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after purchasing an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of IQVIA in the 2nd quarter valued at $514,000. First Trust Advisors LP increased its position in shares of IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after buying an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC raised its stake in IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after buying an additional 1,155 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQV stock opened at $267.34 on Friday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a fifty day simple moving average of $230.54 and a two-hundred day simple moving average of $192.66. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $271.80. The firm has a market capitalization of $44.00 billion, a PE ratio of 33.17, a price-to-earnings-growth ratio of 2.32 and a beta of 1.18.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period last year, the firm earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. The trade was a 57.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the transaction, the insider owned 20,999 shares in the company, valued at $5,232,110.84. This represents a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 15,581 shares of company stock worth $3,796,021. 1.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on IQV shares. Morgan Stanley reaffirmed an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Barclays reissued an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, August 29th. JPMorgan Chase & Co. lifted their target price on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Finally, Robert W. Baird increased their price target on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $243.62.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.